Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
6 Recession-Proof Stocks to Buy as the Market Boom Ends
10:26am, Tuesday, 05'th Jul 2022
These stocks pay dividends, have low payout ratios, low P/E multiples, and good growth. These six stocks are in industries and fields that make them recession-proof stocks, especially given their divi
Why Merck (MRK) Could Beat Earnings Estimates Again
04:10pm, Monday, 04'th Jul 2022 Zacks Investment Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Q3 Likely to Remain Volatile: Top 5 Picks to Stay Safe
11:57am, Monday, 04'th Jul 2022 Zacks Investment Research
We have narrowed our search to five large-cap, low-beta stocks with a solid dividend yield. These are: HSY, LMT, MRK, AEP and CPB.
Oncology ABCs: A Small-Cap Biopharma Prospectus Series
09:30am, Monday, 04'th Jul 2022
Oncology remains the fastest growing pharma segment, where innovation is largely driven by emerging small companies. The global oncology market is estimated at c US$175–180bn and is anticipated to m
A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
09:22am, Monday, 04'th Jul 2022
The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been asso
Q3 Likely to Remain Volatile: Top 5 Picks to Stay Safe
09:18am, Monday, 04'th Jul 2022
We have narrowed our search to five large-cap, low-beta stocks with a solid dividend yield. These are: HSY, LMT, MRK, AEP and CPB.
Dividend Champion, Contender, And Challenger Highlights: Week Of July 3
06:49am, Sunday, 03'rd Jul 2022 Seeking Alpha
Click here to read the weekly summary of dividend activity for Dividend Champions, Contenders, Challengers.
5 Relatively Safe And Cheap Dividend Stocks To Invest In (July 2022)
01:00pm, Saturday, 02'nd Jul 2022 Seeking Alpha
It's always a good idea to keep your wish list ready. How about a list of 5 cos. that are large-cap, safe, dividend-paying, and discounted? Click here.
Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?
08:45pm, Friday, 01'st Jul 2022 Benzinga
The U.S. stock market had a rough start to 2022 with a market correction hitting stocks and many indexes seeing their worst performances in decades.
What Happened: The S&P 500, as tracked by the SPDR
Only 8 Of The 30 Dow Jones Stocks Were Positive In The First Half Of 2022: Chevron Leads, But Who Else Was Up?
04:49pm, Friday, 01'st Jul 2022
The U.S. stock market had a rough start to 2022 with a market correction hitting stocks and many indexes seeing their worst performances in decades. What Happened: The S&P 500, as tracked by the SPDR
Sanofi's (SNY) Studies on BTK Inhibitor Put on Hold by FDA
03:45pm, Friday, 01'st Jul 2022 Zacks Investment Research
Sanofi (SNY) pauses enrollment in late-stage studies evaluating its BTK inhibitor in multiple sclerosis and myasthenia gravis after the FDA places a partial clinical hold on these studies.
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
02:56pm, Friday, 01'st Jul 2022 Zacks Investment Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
Has Merck & Co. (MRK) Outpaced Other Medical Stocks This Year?
01:40pm, Friday, 01'st Jul 2022 Zacks Investment Research
Here is how Merck (MRK) and Patterson Cos. (PDCO) have performed compared to their sector so far this year.
3 Stocks With Solid Records of Sales and Earnings Growth
11:58am, Friday, 01'st Jul 2022
Investors may want to consider the stocks in this article, in my view, since they meet the following value criteria:
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
10:57am, Friday, 01'st Jul 2022 Zacks Investment Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
